Patent: 10,378,058
✉ Email this page to a colleague
Summary for Patent: 10,378,058
| Title: | Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer |
| Abstract: | Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab. |
| Inventor(s): | Yu; Dihua (Houston, TX), Zhou; Xiaoyan (Shanghai, CN), Nagata; Yoichi (Tosu, JP), Esteva; Francisco J. (Bellaire, TX), Sahin; Aysegul A. (Houston, TX) |
| Assignee: | Board of Regents of The University of Texas System (Austin, TX) |
| Application Number: | 12/943,644 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,378,058 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,378,058
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2023-11-05 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2023-11-05 |
| Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2023-11-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
